| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (NCT05365581) | Astellas Pharma Global Development, Inc. | 2022-06-07 |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy (NCT05394740) | National Cancer Center Hospital East | 2022-06-06 |
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels (NCT04931420) | University of Chicago | 2022-05-19 |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (NCT05135845) | Assistance Publique - Hôpitaux de Paris | 2022-03-22 |
| Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma (NCT05034887) | National Cancer Center Hospital East | 2022-01-31 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) (NCT05002127) | ALX Oncology Inc. | 2022-01-15 |
| Multimodal Model Predicts Recurrence (NCT06690268) | Qun Zhao | 2022-01-01 |
| Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer (NCT04999332) | National Cheng-Kung University Hospital | 2021-12-10 |
| Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) (NCT05076279) | Seoul National University Bundang Hospital | 2021-11-15 |
| Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (NCT05177133) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2021-11-05 |
| Gastrectomy Outcomes in Elderly Patients (NCT05071755) | Marmara University | 2021-11-01 |
| Study of FMT Combined With Nivolumab in Gastric Cancer (NCT05001360) | Fujian Cancer Hospital | 2021-10-01 |
| A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma (NCT05008783) | Akeso | 2021-09-17 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer (NCT03042169) | University Hospital, Lille | 2021-08-25 |
| Transcriptomic Signatures in Gastric Adenocarcinoma (NCT05319392) | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 2021-08-06 |
| A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu (NCT05249244) | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | 2021-07-01 |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. (NCT04850729) | Nanfang Hospital, Southern Medical University | 2021-05-25 |
| PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER (NCT07178808) | Banner Health | 2021-04-16 |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NCT04779151) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-04-07 |
| Outcome of Radiation Therapy in Operated Gastric Cancer (NCT04810663) | Assiut University | 2021-04-01 |
| Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors (NCT04764084) | Peking University Cancer Hospital & Institute | 2021-04-01 |
| Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (NCT04499924) | Seagen Inc. | 2021-03-22 |
| Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (NCT04739202) | Hospices Civils de Lyon | 2021-03-19 |
| A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) (NCT04675983) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-03-10 |
| An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study (NCT05056805) | M.D. Anderson Cancer Center | 2021-03-04 |
| Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma (NCT03986502) | Fred Hutchinson Cancer Center | 2021-01-22 |
| Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer (NCT06250075) | Universidade Federal do Amazonas | 2020-12-12 |
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (NCT04111172) | Thomas Jefferson University | 2020-11-10 |
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04682431) | Ikena Oncology | 2020-11-10 |
| Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (NCT04581473) | CARsgen Therapeutics Co., Ltd. | 2020-10-23 |
| Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (NCT04517747) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-15 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (NCT04604132) | Basilea Pharmaceutica | 2020-10-06 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (NCT04430738) | Seagen, a wholly owned subsidiary of Pfizer | 2020-09-15 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma (NCT04523818) | M.D. Anderson Cancer Center | 2020-08-11 |
| Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (NCT04503967) | Shanghai Zhongshan Hospital | 2020-08-01 |
| A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (NCT04363801) | Leap Therapeutics, Inc. | 2020-07-29 |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma (NCT04150640) | University of Wisconsin, Madison | 2020-07-13 |
| Assessment of What Patients and Healthcare Providers Value (NCT04483349) | M.D. Anderson Cancer Center | 2020-06-11 |
| Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study (NCT04065139) | Assistance Publique - Hôpitaux de Paris | 2020-06-11 |
| Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis (NCT04034251) | National Cancer Institute (NCI) | 2020-06-09 |
| Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer (NCT04943406) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2020-05-08 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (NCT03739801) | University of Southern California | 2020-04-06 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer (NCT04162665) | Washington University School of Medicine | 2020-02-14 |
| Registry Platform Gastric/Esophageal Cancer (SAPHIR) (NCT04290806) | iOMEDICO AG | 2019-12-04 |
| Study of the Apatinib Combine With POF Versus POF in Gastric Cancer (NCT04121039) | Fujian Cancer Hospital | 2019-12-01 |
| Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study (NCT04190745) | Zhejiang Cancer Hospital | 2019-11-29 |
| A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (NCT04161781) | Memorial Sloan Kettering Cancer Center | 2019-11-12 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma (NCT04089904) | University of Chicago | 2019-10-11 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT04032704) | Seagen Inc. | 2019-10-09 |
| Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma (NCT04047953) | Peking University Cancer Hospital & Institute | 2019-09-10 |
| TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (NCT04074343) | University of California, Irvine | 2019-08-26 |
| This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) (NCT03780608) | Samsung Medical Center | 2019-07-30 |
| Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (NCT03959293) | Federation Francophone de Cancerologie Digestive | 2019-07-17 |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma (NCT03802591) | CStone Pharmaceuticals | 2019-03-28 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma (NCT03973008) | Zhejiang Cancer Hospital | 2019-03-11 |
| Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study (NCT04194463) | Newcastle-upon-Tyne Hospitals NHS Trust | 2019-02-28 |
| Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma (NCT03788174) | Fujian Cancer Hospital | 2019-02-01 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (NCT03783936) | Ashwin Somasundaram | 2019-01-24 |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma (NCT03852251) | Akeso | 2019-01-18 |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (NCT03735290) | Mendus | 2019-01-14 |
| Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (NCT03776487) | M.D. Anderson Cancer Center | 2019-01-07 |
| TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT03686488) | H. Lee Moffitt Cancer Center and Research Institute | 2018-12-20 |
| Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas (NCT04773769) | Auxilio Mutuo Cancer Center | 2018-11-07 |
| Study of the Combination of Apatinib and POF (NCT03707639) | Fujian Cancer Hospital | 2018-11-01 |
| Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery (NCT03997162) | City of Hope Medical Center | 2018-10-11 |
| Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (NCT03631615) | Shanghai Zhongshan Hospital | 2018-08-20 |
| Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma. (NCT03691454) | Peking University | 2018-06-28 |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms (NCT03468244) | Changhai Hospital | 2018-05-01 |
| OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma (NCT03429816) | University Hospital Heidelberg | 2018-04-15 |
| mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) (NCT03288350) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2018-02-22 |
| Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer (NCT03161522) | M.D. Anderson Cancer Center | 2018-02-19 |
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers (NCT03368963) | Emory University | 2018-01-30 |
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791) | Novartis Pharmaceuticals | 2018-01-24 |
| Phase I Study of the Combination of Apatinib and POF (NCT03244774) | Fujian Cancer Hospital | 2018-01-01 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
| Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma (NCT03141034) | Washington University School of Medicine | 2017-11-01 |
| Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer (NCT03257163) | Rutgers, The State University of New Jersey | 2017-09-29 |
| Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer (NCT03196232) | George Albert Fisher | 2017-09-13 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers (NCT03122548) | Aduro Biotech, Inc. | 2017-08-14 |
| Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (NCT03399071) | Royal Marsden NHS Foundation Trust | 2017-07-31 |
| Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors (NCT03507998) | Curegenix Inc. | 2017-06-17 |
| Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology (NCT03092518) | National Cancer Institute (NCI) | 2017-06-05 |
| A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (NCT03042611) | Elevar Therapeutics | 2017-03-14 |
| A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer (NCT02898077) | Eli Lilly and Company | 2017-03-02 |
| Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers (NCT03246516) | University Hospital, Lille | 2017-02-01 |
| Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma (NCT03814759) | Yonsei University | 2016-12-12 |
| Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer (NCT02830594) | City of Hope Medical Center | 2016-10-05 |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma (NCT02862535) | Gilead Sciences | 2016-09-20 |
| Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer (NCT02891447) | M.D. Anderson Cancer Center | 2016-09-01 |
| Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis (NCT02628951) | Samsung Medical Center | 2016-05-26 |
| Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis (NCT02589496) | Samsung Medical Center | 2016-03-26 |
| Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies (NCT02638909) | Criterium, Inc. | 2015-12-01 |